Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in "a near term milestone payment" as well as $3 million on approval and as much as $132.5 million in sales milestones. Chance will also pay by the carton for Acorda to supply Inbrija to the company. Acorda … [Read more...] about Chance Pharmaceuticals acquires rights to distribute Inbrija levodopa DPI in China
News
FDA accepts Optinose’s sNDA for Xhance, sets PDUFA date
According to Optinose, the FDA has accepted the company's sNDA to expand the use of Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis in patients without nasal polyps and has set the PDUFA target date for completion of its review as December 16, 2023. The FDA approved Xhance for the treatment of nasal polyps in 2017. Optinose submitted … [Read more...] about FDA accepts Optinose’s sNDA for Xhance, sets PDUFA date
Following the sudden death of CEO Lisa Yañez, Anne Whitaker will lead Aerami
Aerami Therapeutics has issued a statement following the death of CEO Lisa Yañez, who was killed in a car accident on May 2, 2023 in Chapel Hill, NC, USA, offering condolences to Yañez's family and announcing that former CEO and current Executive Chairwoman Anne Whitaker will assume leadership of the company. Yañez joined Aerami in June 2022 as Chief Operating … [Read more...] about Following the sudden death of CEO Lisa Yañez, Anne Whitaker will lead Aerami
Strides and Orbicular partner on development of nasal sprays
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According to the announcement, Strides will manufacture the nasal sprays at its facility in Chestnut Ridge, NY, USA … [Read more...] about Strides and Orbicular partner on development of nasal sprays
Bausch Health launches Ryaltris olopatadine / mometasone furoate nasal spray in Canada
Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the nasal spray for the treatment of moderate to severe seasonal allergic rhinitis in September 2022. Ryaltris was approved by the FDA in … [Read more...] about Bausch Health launches Ryaltris olopatadine / mometasone furoate nasal spray in Canada
H&T Presspart and Hovione announce partnership for development of new DPI platform
Device developer and manufacturer H&T Presspart and particle engineering/spray drying specialist Hovione have announced an expansion of their existing relationship with an agreement for development of H&T Presspart's new Sunriser DPI technology. The two companies have previously partnered on development of the PowdAir Plus capsule-based dry powder inhaler. … [Read more...] about H&T Presspart and Hovione announce partnership for development of new DPI platform
Huro Biotech gets manufacturing rights for Destiny Pharma and SporeGen’s SPOR-COV bacillus nasal spray
Destiny Pharma and SporeGen have announced that Vietnamese biotechnology company Huro Biotech has acquired non-exclusive manufacturing rights for SPOR-COV bacillus nasal spray as well as exclusive marketing rights to the nasal spray in Vietnam. Huro has also launched an OTC nasal spray in Vietnam based on SPOR-COV technology, the companies said. In September 2020, … [Read more...] about Huro Biotech gets manufacturing rights for Destiny Pharma and SporeGen’s SPOR-COV bacillus nasal spray
Zambon announces completion of enrollment in Phase 3 studies of inhaled liposomal cyclosporine A for the treatment of BOS
Zambon has announced that the Phase 3 BOSTON-1 and BOSTON-2 trials of liposomal cyclosporine A for inhalation (L-CsA-i) have completed enrollment. The two trials were initiated by Breath Therapeutics in March 2019 prior to that company's acquisition by Zambon. Breath Therapeutics was spun off from PARI Pharma in 2017 to develop L‑CsA‑i, which has received Fast Track … [Read more...] about Zambon announces completion of enrollment in Phase 3 studies of inhaled liposomal cyclosporine A for the treatment of BOS
Copley Scientific launches Impactor Genie IG 200i
Copley Scientific has announced the launch of the Impactor Genie IG 200i semi-automated tool for impaction surface coating and drug dissolution that can be used with either Andersen cascade impactors or Next Generation Impactors. According to Copley, the Impactor Genie IG 200i combines the functions of the new Impactor Coater IC 200i, which can coat collection cups … [Read more...] about Copley Scientific launches Impactor Genie IG 200i
Arrowhead reports interim data from Phase 1/2a trial of ARO-RAGE inhaled RNAi for lung diseases
Arrowhead Pharmaceuticals said that interim data from the ARORAGE-1001 Phase 1/2a trial of its ARO-RAGE inhaled RNAi therapeutic, which it is developing for the treatment of inflammatory lung diseases, demonstrate reductions in soluble receptor for advanced glycation end products (RAGE) as high as 90% in healthy volunteers at the 4th highest dose with no indications … [Read more...] about Arrowhead reports interim data from Phase 1/2a trial of ARO-RAGE inhaled RNAi for lung diseases